Valuation : Sera Prognostics, Inc.

Market Cap 79.69M 68.57M 64.52M 58.94M 110M 7.52B 111M 762M 296M 3.86B 299M 293M 12.44B P/E 2026 *
-3.07x
P/E 2027 * -3.78x
Enterprise Value 79.69M 68.57M 64.52M 58.94M 110M 7.52B 111M 762M 296M 3.86B 299M 293M 12.44B EV / Sales 2026 *
354x
EV / Sales 2027 * 41.4x
Free-Float
85.92%
Yield 2026 *
-
Yield 2027 * -
1 day+2.02%
1 week-2.42%
Current month-4.72%
1 month+4.66%
3 months-10.02%
Current year-31.53%
1 week 1.97
Extreme 1.97
2.18
1 month 1.85
Extreme 1.8514
2.21
Current year 1.56
Extreme 1.56
3.85
1 year 1.56
Extreme 1.56
3.95
3 years 1.37
Extreme 1.37
12.36
5 years 1.1
Extreme 1.1
12.36
10 years 1.1
Extreme 1.1
15.5
Manager TitleAgeSince
Chief Executive Officer 52 2023-05-31
Director of Finance/CFO 47 2026-08-30
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Chairman 74 2011-04-19
Chairman 58 2023-06-07
Director/Board Member 59 2011-10-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/31/26 Free

Chief Financial Officer

287,548 0.7529%
7/10/26 Free

Director

62,657 0.1641%
7/10/26 Free

Director

62,697 0.1642%
Change 5-day change 1-year change 3-year change Capi.($)
+2.02%-2.42%-40.76%+11.60% 78.11M
-0.94%-2.59%+10.78%+12.26% 22.49B
+0.61%-1.79%+15.37%-22.73% 3.68B
-3.87%-9.24%+41.10%+24.41% 3B
-0.28%-0.35%-19.90%-32.94% 2.1B
+0.75%-2.09%-17.39% - 2.04B
+1.79%+2.67%-8.96%+14.74% 1.59B
-2.68%-4.21%+49.31%+85.49% 1.35B
-0.59%+0.87%-16.43%+2.32% 1.34B
-2.41%+10.43%+88.35%+168.90% 1.27B
Average -0.56%-2.90%+10.15%+29.34% 3.89B
Weighted average by Cap. -0.87%-2.38%+12.44%+14.98%

Financials

2026 *2027 *
Net sales 225K 194K 182K 166K 311K 21.24M 312K 2.15M 835K 10.9M 845K 826K 35.11M 1.92M 1.66M 1.56M 1.42M 2.66M 182M 2.67M 18.42M 7.15M 93.25M 7.23M 7.07M 300M
Net income -33.93M -29.2M -27.47M -25.1M -46.95M -3.2B -47.08M -325M -126M -1.64B -127M -125M -5.3B -29.1M -25.04M -23.56M -21.52M -40.26M -2.75B -40.37M -278M -108M -1.41B -109M -107M -4.54B
Net Debt - -
Logo Sera Prognostics, Inc.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
Employees
72
Date Price Change Volume
26-09-04 US$2.020 +2.02% 10,532
26-09-03 US$1.980 -1.49% 15,261
26-09-02 US$2.010 -3.37% 15,379
26-09-01 US$2.080 -1.89% 14,669
26-08-31 US$2.120 +2.42% 9,522
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.020USD
Average target price
5.500USD
Spread / Average Target
+172.28%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SERA Stock